Last updated: May 18, 2026
What MOTS-c is
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide identified in 2015 by Pinchas Cohen’s group at USC. The discovery was significant because MOTS-c is encoded within mitochondrial DNA, not nuclear DNA — making it one of only a handful of mitochondrial-derived peptides (along with humanin, SHLP family).
Mechanism
MOTS-c functions as a “mitokine” — a peptide hormone signaling from mitochondria to other cellular and organ systems. Key effects:
- AMPK activation: Master energy sensor; activation increases catabolism, fat oxidation, glucose uptake
- Nuclear translocation: Under metabolic stress, MOTS-c translocates to the nucleus and regulates gene expression
- Folate-purine pathway modulation: Affects methionine metabolism
- Anti-inflammatory effects: Reduces IL-6 and TNF-α in some models
Effects on metabolism
Animal studies and limited human data show:
- Improved insulin sensitivity
- Increased glucose disposal
- Reduced hepatic glucose production
- Mild reduction in body weight (rodent models)
- Increased exercise capacity
Many of these effects mimic the metabolic adaptations to exercise — leading to MOTS-c being called an “exercise mimetic peptide.”
Age-related decline
MOTS-c circulating levels decline with age:
- Young adults (20-30): ~80-120 ng/mL
- Middle aged (40-60): ~40-80 ng/mL
- Older adults (60+): ~20-40 ng/mL
This decline parallels age-related metabolic decline (reduced insulin sensitivity, sarcopenia, reduced exercise capacity) — supporting the hypothesis that MOTS-c restoration could attenuate metabolic aging.
Research applications
Type 2 diabetes
Animal models show MOTS-c improves insulin sensitivity and reduces hyperglycemia. Phase 1 human trials initiated.
Obesity
Rodent studies show modest weight reduction and improved body composition. Effect size smaller than GLP-1 drugs.
Longevity
Life-extension effects in mouse models. Hypothesis that age-related MOTS-c decline contributes to aging biology.
NAFLD/NASH
Hepatic effects suggest potential application in non-alcoholic fatty liver disease.
Research dosing
Reported research-community protocols use 5-10 mg subcutaneous injection, 2-3 times per week, in cycles of 4-8 weeks. These are not FDA-approved or clinically validated doses.
Safety
Animal toxicology shows favorable safety at studied doses. Limited human data shows good tolerability. Theoretical concerns:
- Modulation of mitochondrial signaling has potential broad effects
- Effects on cancer cell metabolism are complex — could be protective or harmful depending on tumor type
- Long-term human safety unknown
Regulatory status
- US: Sold as research peptide; not FDA-approved
- Clinical trials: Multiple Phase 1 trials initiated 2023-2026
- WADA: Likely banned under metabolic modulator category
Is MOTS-c “exercise in a bottle”?<br />
Animal data supports the comparison — MOTS-c activates many of the same pathways as exercise (AMPK, mitochondrial biogenesis, insulin sensitivity). Human data is limited but mechanism is consistent.
How long until effects show?<br />
4-8 weeks for measurable changes in insulin sensitivity and metabolic markers. Body composition changes are gradual.
Can MOTS-c be combined with GLP-1 drugs?<br />
Different mechanisms suggest compatible combination. No published controlled trial directly tests this.
Is MOTS-c different from humanin?<br />
Both are mitochondrial-derived peptides. Humanin is 21 amino acids and has different functions (predominantly neuroprotective, anti-apoptotic). MOTS-c is metabolism-focused.